LXRX (Lexicon Pharmaceuticals Inc) Earnings per share for the last four quarters

Lexicon Pharma (LXRX) - corporate logo

Lexicon Pharmaceuticals (LXRX) is developing independently of macroeconomic trends, as business success is tied to regulatory approval of new kidney and heart treatments. This chart of EPS (ttm) quotes with a value of 21.20 confirms that the company's progress is driven by clinical data rather than market cycles. Stable demand for diabetes therapy and patent protection create sustainable consumption inertia with high margins.

LXRX lexpharma.com Net earnings per share (EPS TTM) (02/11/2024 - 11/17/2026)

LXRX (Lexicon Pharmaceuticals): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:LXRX (Lexicon Pharmaceuticals Inc)
Core merchandise of Lexicon Corp

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net income per share by comparing the current twelve-month period with the same period last year. This method neutralizes quarterly volatility, separating sustainable operating profitability from one-off financial factors. By analyzing the current EPS YoY shift over the last 12 months, an investor can discern the actual pace of business scaling. For Lexicon Pharmaceuticals (LXRX), this confirms the commercial effectiveness of their targeted drugs in cardiology and endocrinology.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS